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Abstract 50 
Controversies exist with regards to in vivo approaches to delayed immunologically mediated adverse drug 51 
reactions (ADR) such as exanthem (maculopapular eruption), drug reaction with eosinophilia and 52 
systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson 53 
syndrome/toxic epidermal necrolysis, and fixed drug eruption.  In particular,  widespread differences exist 54 
between regions and practice on the availability and use of intradermal testing (IDT) and patch testing, 55 
the standard drug concentrations used, the use of additional drugs in IDT and patch testing to help 56 
determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, 57 
the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed 58 
intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the 59 
science of delayed T-cell mediated reactions that have shed light on immunopathogenesis and provided a 60 
mechanism of pre-prescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and 61 
HLA-B*15:02 and carbamazepine SJS/TEN in Southeast Asians. Future directions should include the 62 
collaboration of large international networks to develop and standardize in vivo diagnostic approaches 63 
such as skin testing and patch testing combined with ex vivo and in vitro laboratory approaches.  64 
Key words:  delayed, intradermal, prick, patch, oral challenge, HLA, AGEP, FDE, DRESS, SJS/TEN 65 
Abbreviations: 66 
ADR    Adverse drug reaction 67 
AGEP  Acute generalized exanthematous pustulosis  68 
DILI Drug-induced liver injury 69 
DRESS   Drug reaction with eosinophilia and systemic symptoms 70 
EAACI   European Academy of Allergy and Clinical Immunology 71 
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ENDA  European Network in Drug Allergy 72 
ESCD  European Society of Contact Dermatitis 73 
FDE      Fixed drug eruption 74 
HLA Human leukocyte Antigen 75 
IDT  Intradermal testing 76 
MPE  Maculopapular drug eruption 77 
SDRIFE Symmetrical drug related intertriginous and flexural exanthema 78 
SJS  Stevens-Johnson syndrome 79 
TCR  T-cell receptor 80 
TEN  Toxic epidermal necrolysis 81 
 82 
Introduction 83 
Delayed immunologically mediated ADR are defined as those that occur more than 6 hours after dosing 84 
(1), with the exception of acute reactions to chemotherapy, which can occur after 6 hours of treatment in 85 
patients premedicated with steroids and anti-histamines). Non-life-threatening adverse drug reactions 86 
such as delayed exanthem are common and occur in approximately 5% of treatment courses with drugs 87 
such as antibiotics, most typically early in the second week of therapy in the case of new sensitization. 88 
Regardless of their specific clinical phenotype, delayed immunologically mediated ADR are mostly T-89 
cell mediated; this includes the typical morbilliform as well as urticarial eruptions, and more complicated 90 
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and life-threatening reactions such as Stevens Johnson syndrome (SJS)/ toxic epidermal necrolysis 91 
(TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and single organ diseases such 92 
as drug-induced liver and kidney diseases (1). Although the typical way of classifying T-cell mediated 93 
reactions has been the revised Gell-Coombs classification, our knowledge of different models by which 94 
drugs activate T cells has advanced considerably over the last 10 years (Figure 1 A and B) (2-5). In 95 
addition, strong HLA Class I associations between severe T-cell mediated reactions such as abacavir 96 
hypersensitivity, SJS/TEN and DRESS that have led to pre-prescription screening strategies (Table 1) (2, 97 
6). It is currently not clear the extent to which exanthems are purely due to parainfectious events to viral 98 
or bacterial antigens or stimulation of the immune system by infectious agents with a secondary 99 
cutaneous reaction to drugs (7). 100 
 101 
Areas of Agreement 102 
Currently, clinical diagnosis is still considered the gold standard for delayed immunologically mediated 103 
ADRs but there is general consensus that in vivo testing, such as patch testing and/or delayed intradermal 104 
testing where sterile preparations of drugs are available, can improve both: (a) the clinical phenotyping of 105 
delayed immunologically mediated ADRs, and (b) the ascertainment of the causative drug where the 106 
patient is taking multiple drugs started about the same time (8, 9). There is also general agreement that 107 
these testing procedures should not be performed for a minimum of 4-6 weeks following the acute 108 
reaction to avoid both false positives, false negatives and flare-up of systemic reactions, although 109 
published evidence to support any of these is weak (8). For abacavir patch testing, which was also used as 110 
a co-primary endpoint in the HLA-B*57:01 testing licensing trial that confirmed the utility of HLA-111 
B*57:01 as a screening test to prevent patch test positive abacavir hypersensitivity, patch tests were 112 
described as reliably positive as early as 4 weeks following reactions, and no patients experienced a 113 
systemic reaction to patch testing (10, 11). Both patch testing and delayed intradermal testing (IDT) have 114 
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also been successfully used to look at potential cross-reactivity between structurally related drugs. For 115 
IDT in particular, although there is agreement to use the highest non-irritating concentration of drugs, 116 
these concentrations have been defined only with regard to immediate reactions. For IDT for many drugs, 117 
the highest non-irritating concentration of the sterile intravenous preparation of drug read after 15-30 118 
minutes may not be similar to that which evokes a T-cell response after 6-24 hours (12, 13). This is 119 
particularly true for drugs such as fluoroquinolones and vancomycin which intrinsically cause direct 120 
release of histamine, and where the sensitivity of IDT using the lowest concentrations to avoid non-IgE 121 
mediated mast cell activation by IDT is very poor (14, 15).  122 
 123 
Controversies and differences across regions 124 
The use of IDT and patch testing for diagnosis of delayed immunologically mediated ADRs has been very 125 
limited to-date in the United States, and there are currently no supportive guidelines in place. This has 126 
been driven by lack of FDA approved reagents for testing and general lack of availability of specialty 127 
centers that prepare and compound drugs for intradermal and patch testing (16). The most established 128 
experience probably exists in Europe, however clinics practicing these procedures also exist in North 129 
America, Asia and Australia amongst others (11, 17-19). There is still a lack of standardized 130 
methodological approaches and particularly inconsistency with regards to the drug concentrations (Table 131 
2) (13, 20, 21). 132 
For in vivo testing, personal and published evidence suggest that IDT is a more sensitive method than 133 
patch testing for reactions such as MPE and may be used when sterile, soluble forms of the drugs are 134 
available (8, 22).   Increasing evidence supports the safety of IDT skin testing for MPE and DRESS 135 
particularly when six or more months has elapsed since the original reaction(8, 23).  A questionnaire in 136 
2004 within the European Network in Drug Allergy (ENDA), the Drug Allergy Interest Group of the 137 
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European Academy of Allergy and Clinical Immunology (EAACI), showed differences in performing 138 
drug allergy investigations (22). Guidelines, such as those by the European Society of Contact Dermatitis 139 
(ESCD) and the EAACI, differ in their recommendations (Table 2), making valid comparison of results 140 
between centers virtually impossible (13, 20). A position paper providing guidelines on drug 141 
concentrations for skin testing was published in 2013, but this paper did not differentiate between the 142 
non-irritating concentrations used in skin prick and IDT for immediate testing versus delayed reactions 143 
(13). This is particularly relevant as IgE-mediated reactions are less dose-dependent, and mechanistic 144 
studies suggest  that the activation of T cells by drug and the subsequent interaction with immune 145 
receptors occurs largely in a non-covalent and a more dose-dependent fashion (2). At the present time, 146 
there is no consensus on the methodology and interpretation of drug IDT. The drug concentration and 147 
method used and the criteria for positivity of skin tests all influence the sensitivity and specificity of IDT; 148 
consequently, thresholds for specific results may vary between different centers. The most reliable 149 
delayed skin test is the IDT, however, delayed positive reactions to prick tests have been described in 150 
DRESS, MPE and AGEP, although less frequently (8). Prick testing is carried out on the volar surface of 151 
the forearm by putting a drop of drug product or a small amount of powder, then the epidermis is 152 
perforated with a special lancet. 153 
Approaches to delayed skin testing differ from that of immediate testing for IgE-mediated reactions where 154 
prick testing is still commonly used and results are compared to those obtained with a negative control 155 
(0.9% serum saline) and a positive control (histamine). They can be performed with all drugs, however 156 
direct histamine releasers such as codeine have to be interpreted with caution. In Europe, for immediate 157 
reactions, the recommendation is to perform reading of prick tests at 20 minutes, and at this time the prick 158 
test is considered positive if the papule (wheal) is greater than or equal to that measured on the negative 159 
control plus 3 millimeters and if there is a surrounding erythema. A prick test has a delayed positive 160 
reaction when there is erythema and infiltration at its test location at 24-48 hours (8, 24). 161 
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For drug patch tests, in Europe, the method is fairly standardized using commercially available patch test 162 
chambers appropriate for the type of vehicle. Patch test tapes typically accommodate solid media such as 163 
a drug compound, most commonly dissolved in petrolatum or another vehicle, but occasionally drugs are 164 
mixed with water and have to be applied to either a filter paper disk placed in the patch test well or patch 165 
test tape with a built in filter. Many academic centers and specialized institutions have responsive 166 
pharmacy services that can compound drugs to the highest non-irritating concentration. The stability of 167 
many patch test materials has not been validated and is most optimally prepared just before testing. It is 168 
also possible to use ready-to-use products in which most drugs are diluted at 10% in petrolatum; 169 
unfortunately only a limited number of molecules marketed by Chemotechnique (Velinge, Sweden) are 170 
available in some European countries.  For certain drugs that are commonly associated with contact 171 
reactions such as corticosteroids and neomycin commercially available topical preparations of the drugs 172 
are used in patch testing.  More recently, a method for compounding drug in the clinic setting by 173 
physicians and other providers was described that appeared equivalent to pharmacy prepared and 174 
commercially available patch test reagents in sensitivity and specificity (25). In most of the cases, it is 175 
necessary to prepare the test material by diluting the drugs in their marketed form.  176 
For drug patch testing, there are numerous recommendations on the dilutions to be used (20, 21). Two 177 
sets of European guidelines have been published for clinicians to conduct drug patch tests with the drug in 178 
its commercially available form with each drug diluted to 30% (20) or 20% (21) in petrolatum. Ideally, a 179 
concentration of 10% of active ingredient should be obtained. Brajon et al. (26) showed that the exact 180 
amount of the active ingredient in diluted commercial forms of drugs prepared at 30% in petrolatum 181 
varied from 0.05% to 30% and that 25% of the DPTs had an active ingredient’s concentration of less than 182 
2%. Testing the drug “as is” on filter paper chambers for non-irritating drugs may show some promise, 183 
but  further studies are needed. Who performs testing also differs widely across geographical regions. 184 
Although there is a lack of published evidence, in the United States, it is uncommon for allergists, 185 
immunologists or dermatologists to do drug allergy testing by either prick, IDT or patch testing. This was 186 
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supported by a recent survey of Allergy and Immunology program directors in the United States(16). In 187 
Europe, dermatologists are more widely available than allergists in many countries and are more likely to 188 
perform both patch testing and to a lesser extent delayed IDT (16). 189 
For both delayed IDT and patch testing, it has been recommended that, when possible, corticosteroids and 190 
other immunosuppressants are stopped one month prior to testing. The site of patch testing has most 191 
commonly been the upper flat part of the back for pragmatic reasons, although this may be the region 192 
with the lowest density of resident T cells and the relative sensitivity of the back versus other sites for 193 
patch testing is unknown (11, 20). The exception is for fixed drug eruptions (FDE) where the sensitivity is 194 
very poor unless the patch test is applied at the site of the previous reaction. 195 
The utility and challenges of ex vivo assays such as interferon-γ ELISpot and in vitro assays such as 196 
lymphocyte transformation test has been described in detail during the International Drug Allergy 197 
Symposium (27).  These tests have many of the same challenges as in vivo testing with regards to the 198 
need for standardization and validation for different drugs and phenotypes. Their negative predictive 199 
value is currently not adequate to justify unsupervised rechallenge with potentially implicated drugs in 200 
most settings (1, 28). More recent work suggests that combining laboratory based ex vivo and/or in vitro 201 
assays with delayed IDT and patch testing may significantly increase the diagnostic sensitivity (17). 202 
In combination with skin tests when applicable, oral provocation test or challenge test is still considered 203 
the gold standard diagnostic procedure for determination of the culprit drug. For immediate reactions, a 204 
single or graded dose challenge is considered adequate to exclude an immediate or IgE mediated reaction 205 
(29, 30).  For delayed reactions in the case of a clear history of a documented benign exanthem, a single 206 
dose challenge is considered safe (31). However in the setting of a more remote reaction, it may not be 207 
adequate to ascertain tolerance of defined daily doses or a full treatment cycle. A single dose challenge 208 
may also be dangerous in the setting of more severe reactions such as severe cutaneous adverse drugs 209 
reactions (SCAR) where a single dose has been described to reproduce a reaction particularly in the 210 
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setting of a more recent reaction. There is significant lack of consensus for selecting patients who would 211 
be appropriate candidates for undergoing oral provocation or challenge following negative delayed IDT 212 
or patch testing. For those patients with a history of a mild exanthem and negative delayed patch and/or 213 
intradermal testing, it would be common after a tolerated single dose challenge for a 3, 5 or 7 day 214 
challenge with an antibiotic such as amoxicillin to be negative. Hence the procedure of multiple day 215 
challenge is currently not endorsed and provocation tests lasting several days with antibiotics are debated 216 
currently because of the minimal and theoretical risk of inducing antibiotic resistance or sensitization. 217 
Other groups have proposed going straight to oral challenge without the previous skin testing step for 218 
these benign reactions (30). A caveat to this for delayed reactions and particularly those remote in nature, 219 
is that a single dose challenge can be negative and the reaction may potentially be picked up on the 220 
second or subsequent doses only. However, the negative predictive value of provocation tests has been 221 
reassuring (>90%) for cutaneous adverse drug reactions (32) or beta-lactam antibiotic induced delayed 222 
reactions (33, 34). Oral challenge is avoided in the setting of positive IDT or patch tests. 223 
For benign exanthems, there is some evidence to suggest that, in the case of an acute exanthem and if the 224 
drug (an antibiotic) is still indicated, it can be continued with at least a temporary clinical tolerance (35). 225 
For patients with a history of a benign exanthem who have stopped the drug but require it in the future, 226 
there is relative consensus amongst groups for the use of graded reintroduction or a more prolonged 227 
desensitization over several hours or days, although the mechanism by which these procedures work is 228 
not known. One goal for an international standardization will be to define what a benign delayed 229 
exanthem is and under which circumstances the potential inconvenience and symptoms of the rash 230 
outweigh the clinical necessity of drug treatment. SCAR and other severe delayed drug reactions such as 231 
drug-induced liver injury are generally considered contraindications to rechallenge. In general, if there is 232 
an effective alternative drug, the implicated and structurally related drugs should not be reintroduced. 233 
Exceptions to this exist in low and middle income countries where diseases of high global burden, such as 234 
HIV and tuberculosis, demand complex treatment regimens and where immunologically-mediated ADRs 235 
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may significantly restrict treatment options (1). In these cases, where the risk of morbidity and mortality 236 
from the underlying disease outweighs or at least equals the risk of morbidity and mortality from the drug 237 
reaction, the risk/benefit ratio sways towards sequential rechallenge of potentially implicated drugs. The 238 
availability of in vivo and ex vivo testing to guide rechallenge choices would be extremely helpful in these 239 
settings.   240 
Significant knowledge gaps still exist in terms of use of combinations of genetic, in vivo skin testing and 241 
ex vivo/in vitro diagnostic testing for delayed reactions. Given the lack of 100% negative predictive value 242 
of any one diagnostic approach, combined approaches are likely to be necessary. In addition, much like 243 
the knowledge gaps that exist in the treatment of SCAR, advances in knowledge of the 244 
immunopathogenesis will drive the discovery of both therapeutic and diagnostic targets. 245 
 246 
Consensus Recommendations and Future Directions   247 
• There is a need for additional evidence and standardization of approaches to the diagnosis of 248 
delayed immunologically mediated ADR in multicenter studies and potential opportunities to 249 
incorporate this into treatment intervention studies. 250 
• Standardization of clinical diagnosis is important to studies looking at the efficacy of diagnostic 251 
approaches to delayed immunologically mediated ADR. 252 
• A consensus committee should focus on standardization of procedures for the most common 253 
drugs and phenotypes with the highest yield that will have the most clinical impact. 254 
• Current literature supports the use of patch testing and delayed IDT in specific phenotypes (table 255 
3). 256 
• The highest utility of in vivo testing approaches will be the combination of exemplary phenotype 257 
standardization with ex vivo and in vitro laboratory based testing (27); however a greater evidence 258 
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base is needed for  not only what combinations of tests to use but when to perform testing 259 
following an acute reaction. 260 
• For in vivo testing for delayed reactions, and in particular for delayed IDT, there is a need for 261 
harmonization of approaches, study of and standardization of drug concentrations, vehicles, 262 
preparation and knowledge on stability of test solutions. 263 
• Given the rarity of SCAR, large collaborative networks are needed to study the sensitivity, 264 
specificity and safety of IDT and patch testing in these populations, as well as validating the 265 
approach such as optimal time since reaction to testing, concentration of drugs and/or metabolites 266 
and the utility of these approaches, particularly when combined with ex vivo and in vitro testing 267 
in ascertaining the implicated drug, potential cross-reactive drugs and safe future drug choices. 268 
• Additional scientific advances into knowledge of immunopathogenesis of these reactions may 269 
answer many key questions and will drive strategies for improved prevention, diagnosis and 270 
treatment. 271 
 272 
 273 
  274 
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Table 1: HLA Associations with Delayed IM-ADR and Implications for Translation 275 
 276 
Table 1:  Recently Described HLA Associations with Delayed Drug Reactions 277 
Drug Phenotype  HLA Allele 
 
HLA Risk 
Allele 
Prevalence 
Disease 
Prevalence 
OR NPV PPV NNT Current Use 
as Screening 
Test 
Abacavir 
Hypersensitivity 
Syndrome(2, 10, 
36) 
B*57:01 5-8% European 
ancestry 
<1% 
African/Asia 
2.5% African 
American 
8% (3% true 
HSR and 2-7% 
false positive 
diagnosis 
960 100% for 
patch test 
confirmed 
55% 13 Routine in 
HIV clinical 
practice in 
developed 
world 
Allopurinol 
SJS/TEN and 
DRESS/DIHS(2, 
37, 38) 
B*58:01 9-11% Han 
Chinese 
1-6% European 
ancestry# 
1/250-1/1000 580 100% (Han 
Chinese, 
Southeast 
Asian)* 
3% 250 Selectively 
used^ 
Carbamazepine  
SJS/TEN(2, 39) 
B*15:02# 10-15% Han 
Chinese 
<1% Koreans, 
Japanese 
<0.1% 
European 
Ancestry 
1-4% (Han 
Chinese) 
 
>1000 100% (Han 
Chinese, 
East Asian)  
 
3% 
 
 
 
1000 
 
 
 
Routine in 
many 
Southeast 
Asian 
countries 
 14 
Dapsone 
DRESS/DHIS(2, 
40) 
B*13:01 2-20% Chinese 
28% 
Papuans/Austral
ian Aboriginals 
0% 
European/Afric
an 
1.5% Japanese 
<2% African 
and African 
American 
 
1-4% Han 
Chinese 
20 99.8% (Han 
Chinese, 
East Asian) 
7.8% 84 Screening 
programs 
implemented 
in China and 
Southeast Asia 
where leprosy 
prevalent 
Flucloxacillin(41) B*57:01 5-8% European 
ancestry 
<1% 
African/Asia 
2.5% African 
American 
8.5/100,000 81 99.99 0.14
% 
13819 No 
NNT = Number needed to test to prevent one case of disease; +other alleles of B75 serotype (HLA-B*15:21, B*15:11; B*15:08 278 
*From RegiSCAR data approximately 60% of Europeans with allopurinol SJS/TEN carry HLA-B*58:01 and HLA risk alleles other than HLA-279 
B*58:01 are thought to be relevant in those of European and African origin; ^may have increased utility in patients at higher risk with renal 280 
insufficiency and because of high cost of alternatives (febuxostat) and low positive predictive value adoption has varied.#HLA-B*15:02 is 281 
associated with SJS/TEN in Southeast Asians but not DRESS or MPE.  HLA-A*31:01 is more prevalent in Europeans and Japanese associated 282 
with carbamazepine DRESS and MPE and prospective evidence for decreased SCAR with HLA-A*31:01 screening in Japanese(42-44).283 
 15 
 284 
 285 
  286 
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Table 2: Comparison of international guidelines published for performing delayed intradermal tests 287 
 288 
 ESCD (14) EAACI (15) 
Volume injected  0.04 ml 
(in saline or 
phenolated saline) 
0.02 to 0.05 ml 
Criteria for 
delayed positivity 
Papule at 24h 24-72 h 
infiltrated 
erythema 
 
Site Volar aspect of 
forearm or extensor 
aspect of upper arm 
Volar aspect of the 
forearm (or other 
regions) 
Negative control 
with saline 
Yes Yes 
Positive control 
specific for 
delayed response 
No No 
 289 
ESCD: European Society of Contact Dermatitis, EAACI : European Academy of Allergy and Clinical 290 
Immunology 291 
 292 
  293 
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Table 3: Use of Delayed Prick/Intradermal, Patch Testing and Systemic Provocation for Delayed 294 
Reactions (8, 9, 23, 24)+  295 
 Patch tests*  Prick tests  IDT^ Systemic 
Provocation 
Maculopapular 
rash  
Useful (positive in 
10-40%) 
Potentially useful Potentially useful 
however direct 
oral provocation 
maybe indicated 
in low 
probability 
situations 
After negative 
skin tests with 
delayed readings 
in low probability 
situations. NPV 
of 90%. 
Generalized 
eczema  
(Contact reaction) 
Useful Potentially useful Potentially useful  After negative 
delayed skin test 
with delayed 
readings. NPV is 
unknown 
Baboon syndrome 
or SDRIFE  
Useful (positive in 
52-82%) 
Potentially useful Potentially useful After negative 
skin tests with 
delayed readings. 
NPV is unknown 
Fixed drug 
eruption  
Useful with in situ 
application in area 
of previous 
reaction (up to 
40% positive)  
Unknown Unknown At full dose when 
patch tests or 
repeated 
application tests 
are negative. 
NPV is unknown. 
Photosensitization Photopatch tests 
with a 5 joule 
exposure to UVA, 
Irradiation at 48 h. 
No value No value No value without 
exposure to UV 
Acute generalized 
exanthematous 
pustulosis  
Useful – 
sensitivity depends 
on the specific 
implicated drug 
(up to 58%)   
Unknown 
  
Potentially useful Systemic 
provocation of 
suspected drug or 
cross-reactive 
drugs is 
contraindicated. 
DRESS  Useful (positive in 
32-64% ) 
dependent on drug 
 
Advised 6 months 
after 
Described delayed 
positive at 24 
hours but unknown 
utility  
Delayed reading 
at 24 hours 
Currently 
unknown safety  
Systemic 
provocation with 
the highly 
suspected drug 
and cross-
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disappearance of 
rash and other 
sequelae 
reactive drugs 
contraindicated.   
SJS/TEN Low sensitivity 
(<30%). Can be 
considered if there 
is benefit of 
diagnostic 
information 
obtained# 
Considered 
contraindicated 
Considered 
contraindicated  
Systemic 
provocation with 
the suspected 
drug is 
contraindicated. 
Drug-induced liver 
disease (or another 
single organ 
phenotype) 
Low sensitivity if 
no cutaneous 
involvement 
Low sensitivity if 
no cutaneous 
involvement 
Low sensitivity 
if no cutaneous 
involvement 
Systemic 
provocation with 
the suspected 
drug is 
contraindicated. 
*initial read at 48 hours; reading at 72, 96 hours and 1 weeks if initial negative; ^read at 48 hours if 24 hours 296 
negative.+Practices differ significantly between the United States and Europe and parts of Asia at this time. In 297 
Europe both allergists and dermatologists perform both skin testing, patch testing and systemic provocation. In the 298 
US allergists perform mainly skin testing and oral provocation and there are few canters where delayed testing is 299 
offered.  Drug patch testing and delayed IDT is not frequently offered in the United States by either allergists or 300 
dermatologists and is offered in select centers only.#For allopurinol and its metabolite oxypurinol patch testing has 301 
had 0% sensitivity. 302 
 303 
 304 
Figure Legends 305 
Figure 1.  A.  Extended Gell & Coombs Classification of Delayed T-cell mediated adverse drug 306 
reactions.  AGEP, acute generalized exanthematous pustulosis; CTL, cytotoxic T lymphocyte; CXCL8, 307 
chemokine 8; GM-CSF granulocyte-macrophage colony stimulating factor; IFN-γ (interferon-γ); IL-308 
interleukin, PMN, polymorphonuclear neutrophil, DRESS, drug reaction with eosinophilia and systemic 309 
symptoms; Stevens-Johnson Syndrome/Toxic epidermal necrolysis (SJS/TEN); Th1, helper T cell type 1; 310 
Th2, helper T cells type2: TNF-α, tumor necrosis factor-α,(adapted from Pichler et al). Frames below 311 
show representative clinical pictures: IVa (positive delayed intradermal to 1% lidocaine in patient with 312 
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contact reaction to lidocaine (L) without demonstrable cross-reactivity to mepivacaine (C), IVb 313 
(maculopapular exanthem); IVc (TEN); IVd (AGEP) 314 
B. Proposed mechanisms of T-cell mediated reactions including the hapten/prohapten model, the 315 
pharmacological-interaction model and the altered peptide repertoire model that provide a proposed 316 
model for how drugs activate T cells.  The hapten-prohapten model shows the drug covalently binds to a 317 
peptide either intracellularly in the endoplastic reticulum prior to peptide processing and presentation or at 318 
the cell surface    The pharmacological interaction model (p-i) shows the drug non-covalently binding to 319 
the HLA-molecule and/or T-cell receptor to result in direct T-cell activation.  The altered peptide 320 
repertoire model shows a drug binding non-covalently in the HLA antigen binding cleft that alters the 321 
repertoire of self-peptide ligands leading to presentation of novel peptide ligands that are recognized as 322 
foreign and elicit an immune response. TCR – T-cell receptor. 323 
 324 
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